The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Journal of Neurochemistry

Volumn 101, Issue 1, 2007, Pages 87-98

  Shoemaker, Jennifer L ^a   Seely, Kathryn A ^a   Reed, Ronald L ^a   Crow, John P ^a   Prather, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

AM 1241; Amyotrophic lateral sclerosis; CB1 cannabinoid receptor; CB2 cannabinoid receptor; G93A SOD1 transgenic mice; WIN 55,212

Indexed keywords

2,3 DICHLOROPHENYL [5 METHOXY 2 METHYL 3 (2 MORPHOLIN 4 YLETHYL)INDOL 1 YL]METHANONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; COPPER ZINC SUPEROXIDE DISMUTASE; DEXANABINOL; GW 405833; N (2 CYCLOETHYL) 5,8,11,14 EICOSATETRAENAMIDE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RECEPTOR BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPINAL CORD; SURVIVAL; TRANSGENIC MOUSE; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BINDING, COMPETITIVE; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL RATE; TREATMENT OUTCOME; UP-REGULATION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 33947278309     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04346.x     Document Type: Article

References (61)

1. Baker D., Pryce G., Davies W. L. and Hiley C. R. (2006) In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27, 1-4.
2. Benito C., Nunez E., Tolon R. M., Carrier E. J., Rabano A., Hillard C. J. and Romero J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11 136-11 141.
3. Bensimon G. and Doble A. (2004) The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin. Drug Saf. 3, 525-534.
4. Bilsland L. G., Dick J. R., Pryce G., Petrosino S., Di Marzo V., Baker D. and Greensmith L. (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20, 1003-1005.
5. Breivogel C. S., Griffin G., Di Marzo V. and Martin B. R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60, 155-163.
6. Bruijn L. I., Miller T. M. and Cleveland D. W. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749.
7. Cleveland D. W. and Rothstein J. D. (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806-819.
8. Crow J. P., Calingasan N. Y., Chen J., Hill J. L. and Beal M. F. (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 58, 258-265.
9. Di Marzo V., Bifulco M. and De Petrocellis L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771-784.
10. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J. and Shytle D. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2, 29.
11. Felder C. C., Joyce K. E., Briley E. M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A. L. and Mitchell R. L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443-450.
12. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G. and Casellas P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61.
13. Gardner A. and Mallet P. E. (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur. J. Pharmacol. 530, 103-106.
14. Gatley S. J., Lan R., Pyatt B., Gifford A. N., Volkow N. D. and Makriyannis A. (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61, PL191-PL197.
15. Giulietti A., Overbergh L., Valckx D., Decallonne B., Bouillon R. and Mathieu C. (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25, 386-401.
16. Gong J. P., Onaivi E. S., Ishiguro H., Liu Q. R., Tagliaferro P. A., Brusco A. and Uhl G. R. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10-23.
17. Gordon P. H. (2005) Advances in clinical trials for amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 5, 48-54.
18. Gurney M. E. (1997) Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. 244(Suppl 2), S15-20.
19. Hanisch U. K. (2002) Microglia as a source and target of cytokines. Glia 40, 140-155.
20. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1990) Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932-1936.
21. Hillard C. J., Manna S., Greenberg M. J., Di Camelli R., Ross R. A., Stevenson L. A., Murphy V., Pertwee R. G. and Campbell W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289, 1427-1433.
22. Hosohata K., Quock R. M., Hosohata Y., Burkey T. H., Makriyannis A., Consroe P., Roeske W. R. and Yamamura H. I. (1997) AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci. 61, PL115-PL118.
23. Ince P. G., Shaw P. J., Slade J. Y., Jones C. and Hudgson P. (1996) Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol. (Berl.) 92, 395-403.
24. Jung C., Rong Y., Doctrow S., Baudry M., Malfroy B. and Xu Z. (2001) Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. 304, 157-160.
25. Kiaei M., Kipiani K., Chen J., Calingasan N. Y. and Beal M. F. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191, 331-336.
26. Kiaei M., Petri S., Kipiani K. et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 26, 2467-2473.
27. Kieran D., Kalmar B., Dick J. R., Riddoch-Contreras J., Burnstock G. and Greensmith L. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 10, 402-405.
28. Kirkinezos I. G., Hernandez D., Bradley W. G. and Moraes C. T. (2004) An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem. 88, 821-826.
29. Klein T. W. (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5, 400-411.
30. Maresz K., Carrier E. J., Ponomarev E. D., Hillard C. J. and Dittel B. N. (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 95, 437-445.
31. Mathison R., Ho W., Pittman Q. J., Davison J. S. and Sharkey K. A. (2004) Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br. J. Pharmacol. 142, 1247-1254.
32. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
33. McGeer P. L. and McGeer E. G. (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470.
34. Munro S., Thomas K. and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
35. Nelson P. T., Soma L. A. and Lavi E. (2002) Microglia in diseases of the central nervous system. Ann. Med. 34, 491-500.
36. Prather P. L., Martin N. A., Breivogel C. S. and Childers S. R. (2000a) Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol. 57, 1000-1010.
37. 2+ channels in transfected rat pituitary cells. J. Pharmacol. Exp. Ther. 295, 552-562.
38. Raman C., McAllister S. D., Rizvi G., Patel S. G., Moore D. H. and Abood M. E. (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 33-39.
39. Ramirez B. G., Blazquez C., Gomez del Pulgar T., Guzman M. and de Ceballos M. L. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913.
40. Rinaldi-Carmona M., Barth F., Millan J. et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650.
41. Rothstein J. D., Patel S., Regan M. R. et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77.
42. Shoemaker J. L., Joseph B. K., Ruckle M. B., Mayeux P. R. and Prather P. L. (2005) The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther. 314, 868-875.
43. Steffens S., Veillard N. R., Arnaud C., Pelli G., Burger F., Staub C., Karsak M., Zimmer A., Frossard J. L. and Mach F. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786.
44. Streit W. J. (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40, 133-139.
45. Strong M. and Rosenfeld J. (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4, 136-143.
46. Tortarolo M., Grignaschi G., Calvaresi N. et al. (2006) Glutamate AMPA receptors change in motor neurons of SOD1(G93A) transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J. Neurosci. Res. 83, 134-146.
47. Traynor B. J., Alexander M., Corr B., Frost E. and Hardiman O. (2003) An outcome study of riluzole in amyotrophic lateral sclerosis - a population-based study in Ireland, 1996-2000. J. Neurol. 250, 473-479.
48. Turner M. R., Cagnin A., Turkheimer F. E., Miller C. C., Shaw C. E., Brooks D. J., Leigh P. N. and Banati R. B. (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 15, 601-609.
49. Valenzano K. J., Tafesse L., Lee G. et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48, 658-672.
50. Van Den Bosch L., Tilkin P., Lemmens G. and Robberecht W. (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13, 1067-1070.
51. Van Sickle M. D., Duncan M., Kingsley P. J. et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
52. Walter L. and Stella N. (2004) Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141, 775-785.
53. Wang R. and Zhang D. (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur. J. Neurosci. 22, 2376-2380.
54. West M., Mhatre M., Ceballos A. et al. (2004) The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J. Neurochem. 91, 133-143.
55. Weydt P. and Moller T. (2005) Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport 16, 527-531.
56. Weydt P., Hong S., Witting A., Moller T., Stella N. and Kliot M. (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6, 182-184.
57. Witting A., Weydt P., Hong S., Kliot M., Moller T. and Stella N. (2004) Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89, 1555-1557.
58. Wu A. S., Kiaei M., Aguirre N., Crow J. P., Calingasan N. Y., Browne S. E. and Beal M. F. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurochem. 85, 142-150.
59. Yao B. B., Mukherjee S., Fan Y., Garrison T. R., Daza A. V., Grayson G. K., Hooker B. A., Dart M. J., Sullivan J. P. and Meyer M. D. (2006) In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB(2) receptor? Br. J. Pharmacol. 149, 145-154.
60. Yiangou Y., Facer P., Durrenberger P., Chessell I. P., Naylor A., Bountra C., Banati R. R. and Anand P. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/ macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6, 12.
61. Zhang W., Narayanan M. and Friedlander R. M. (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53, 267-270.